RHJA
CSTL icon

Rice Hall James & Associates’s Castle Biosciences CSTL Stock Holding History

Rice Hall James & Associates’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-26,750
Closed -$587K – 268
2022
Q2 		$587K Buy
26,750
+599
+2% +$13.9K 0.03% 242
2022
Q1 		$1.17M Buy
26,151
+938
+4% +$38.8K 0.05% 235
2021
Q4 		$1.08M Sell
25,213
-3,531
-12% -$185K 0.04% 243
2021
Q3 		$1.91M Sell
28,744
-5,593
-16% -$394K 0.07% 214
2021
Q2 		$2.52M Sell
34,337
-1,482
-4% -$97.9K 0.09% 179
2021
Q1 		$2.45M Buy
35,819
+11
+0% +$827 0.08% 178
2020
Q4 		$2.4M Buy
35,808
+2,367
+7% +$128K 0.08% 160
2020
Q3 		$1.72M Buy
33,441
+10,595
+46% +$471K 0.07% 183
2020
Q2 		$861K Buy
22,846
+286
+1% +$9.77K 0.04% 218
2020
Q1 		$673K Buy
+22,560
New +$681K 0.04% 222

Other funds holding CSTL

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
KCM
Kornitzer Capital Management Shawnee Mission, Kansas $4.65B AUM 23.83% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Rice Hall James & Associates's CSTL Position: Q3 2022 in Review

Rice Hall James & Associates sold out of Castle Biosciences (CSTL) in Q3 2022, closing a stake of 26,750 shares — an estimated $587K sold.

Rice Hall James & Associates first reported a position in CSTL in Q1 2020 and held it in 10 quarters. The position peaked at $2.52M in Q2 2021. 157 funds tracked by Wall St. Rank hold CSTL as of Q3 2022.

  • Rice Hall James & Associates reported no remaining Castle Biosciences position as of Q3 2022 after selling out during the quarter.
  • Rice Hall James & Associates sold 26,750 Castle Biosciences shares in Q3 2022, an estimated $587K.
  • Rice Hall James & Associates first reported a position in Castle Biosciences in Q1 2020 and held it in 10 quarters.
  • Rice Hall James & Associates's Castle Biosciences position peaked at $2.52M in Q2 2021.
  • 157 funds tracked by Wall St. Rank held Castle Biosciences as of Q3 2022.

Based on Rice Hall James & Associates's 13F filing for Q3 2022, filed 1 Nov 2022.